APO RESEARCH · REPORT
Conjunctivitis
Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.
Product & engineering
Understand the product.
Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.
Conjunctivitis is more commonly referred to as pink eye. The whites of the eyes appear pink or red when the conjunctiva (the transparent membrane which lines part of the eyeball) becomes inflamed or infected.
Selected research
Industry Research
Conjunctivitis Industry Research Report 2026
Market perspective
Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.
Conjunctivitis is more commonly referred to as pink eye. The whites of the eyes appear pink or red when the conjunctiva (the transparent membrane which lines part of the eyeball) becomes inflamed or infected.
The technical barriers of conjunctivitis industry are existed apparently. The key technology and higher level products are in the hand of the global leading enterprise like Novartis, Santen Pharmaceutical, Bausch + Lomb, Allergan, Sun Pharmaceutical, Akorn and Sinqi, etc.
Read the full market overview
Report Scope
This report quantifies the global Conjunctivitis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Conjunctivitis Market by Company
Novartis (CH)
Santen Pharmaceutical (JP)
Bausch & Lomb (US)
Allergan (US)
Sun Pharmaceutical (ID)
Akorn (US)
Freda (CN)
Sinqi (CN)
Univision (CN)
Conjunctivitis Segment by Type
Antibiotic
Pills
Ointment
Conjunctivitis Segment by End User
Newborns
Children
Adults
Conjunctivitis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Conjunctivitis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Conjunctivitis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Conjunctivitis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Conjunctivitis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Conjunctivitis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Conjunctivitis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by end user, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antibiotic
- Pills
- Ointment
Applications
- Newborns
- Children
- Adults
Companies covered
- Novartis (CH)
- Santen Pharmaceutical (JP)
- Bausch & Lomb (US)
- Allergan (US)
- Sun Pharmaceutical (ID)
- Akorn (US)
- Freda (CN)
- Sinqi (CN)
- Univision (CN)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Conjunctivitis Market Size (2021-2032)
- 2.2.2 Global Conjunctivitis Sales (2021-2032)
- 2.2.3 Global Conjunctivitis Market Average Price (2021-2032)
- 2.3 Conjunctivitis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antibiotic
- 2.3.3 Pills
- 2.3.4 Ointment
- 2.4 Conjunctivitis by End User
- 2.4.1 Market Value Comparison by End User (2021 VS 2025 VS 2032)
- 2.4.2 Newborns
- 2.4.3 Children
- 2.4.4 Adults
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Conjunctivitis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Conjunctivitis Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Conjunctivitis Revenue of Manufacturers (2021-2026)
- 3.4 Global Conjunctivitis Average Price by Manufacturers (2021-2026)
- 3.5 Global Conjunctivitis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Conjunctivitis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Conjunctivitis, Product Type & Application
- 3.8 Global Manufacturers of Conjunctivitis, Established Date
- 3.9 Global Conjunctivitis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis (CH)
- 4.1.1 Novartis (CH) Company Information
- 4.1.2 Novartis (CH) Business Overview
- 4.1.3 Novartis (CH) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis (CH) Conjunctivitis Product Portfolio
- 4.1.5 Novartis (CH) Recent Developments
- 4.2 Santen Pharmaceutical (JP)
- 4.2.1 Santen Pharmaceutical (JP) Company Information
- 4.2.2 Santen Pharmaceutical (JP) Business Overview
- 4.2.3 Santen Pharmaceutical (JP) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Santen Pharmaceutical (JP) Conjunctivitis Product Portfolio
- 4.2.5 Santen Pharmaceutical (JP) Recent Developments
- 4.3 Bausch & Lomb (US)
- 4.3.1 Bausch & Lomb (US) Company Information
- 4.3.2 Bausch & Lomb (US) Business Overview
- 4.3.3 Bausch & Lomb (US) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bausch & Lomb (US) Conjunctivitis Product Portfolio
- 4.3.5 Bausch & Lomb (US) Recent Developments
- 4.4 Allergan (US)
- 4.4.1 Allergan (US) Company Information
- 4.4.2 Allergan (US) Business Overview
- 4.4.3 Allergan (US) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Allergan (US) Conjunctivitis Product Portfolio
- 4.4.5 Allergan (US) Recent Developments
- 4.5 Sun Pharmaceutical (ID)
- 4.5.1 Sun Pharmaceutical (ID) Company Information
- 4.5.2 Sun Pharmaceutical (ID) Business Overview
- 4.5.3 Sun Pharmaceutical (ID) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sun Pharmaceutical (ID) Conjunctivitis Product Portfolio
- 4.5.5 Sun Pharmaceutical (ID) Recent Developments
- 4.6 Akorn (US)
- 4.6.1 Akorn (US) Company Information
- 4.6.2 Akorn (US) Business Overview
- 4.6.3 Akorn (US) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Akorn (US) Conjunctivitis Product Portfolio
- 4.6.5 Akorn (US) Recent Developments
- 4.7 Freda (CN)
- 4.7.1 Freda (CN) Company Information
- 4.7.2 Freda (CN) Business Overview
- 4.7.3 Freda (CN) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Freda (CN) Conjunctivitis Product Portfolio
- 4.7.5 Freda (CN) Recent Developments
- 4.8 Sinqi (CN)
- 4.8.1 Sinqi (CN) Company Information
- 4.8.2 Sinqi (CN) Business Overview
- 4.8.3 Sinqi (CN) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sinqi (CN) Conjunctivitis Product Portfolio
- 4.8.5 Sinqi (CN) Recent Developments
- 4.9 Univision (CN)
- 4.9.1 Univision (CN) Company Information
- 4.9.2 Univision (CN) Business Overview
- 4.9.3 Univision (CN) Conjunctivitis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Univision (CN) Conjunctivitis Product Portfolio
- 4.9.5 Univision (CN) Recent Developments
5 Global Conjunctivitis Market Scenario by Region
- 5.1 Global Conjunctivitis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Conjunctivitis Sales by Region: 2021-2032
- 5.2.1 Global Conjunctivitis Sales by Region: 2021-2026
- 5.2.2 Global Conjunctivitis Sales by Region: 2027-2032
- 5.3 Global Conjunctivitis Revenue by Region: 2021-2032
- 5.3.1 Global Conjunctivitis Revenue by Region: 2021-2026
- 5.3.2 Global Conjunctivitis Revenue by Region: 2027-2032
- 5.4 North America Conjunctivitis Market Facts & Figures by Country
- 5.4.1 North America Conjunctivitis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Conjunctivitis Sales by Country (2021-2032)
- 5.4.3 North America Conjunctivitis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Conjunctivitis Market Facts & Figures by Country
- 5.5.1 Europe Conjunctivitis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Conjunctivitis Sales by Country (2021-2032)
- 5.5.3 Europe Conjunctivitis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Conjunctivitis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Conjunctivitis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Conjunctivitis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Conjunctivitis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Conjunctivitis Market Facts & Figures by Country
- 5.7.1 South America Conjunctivitis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Conjunctivitis Sales by Country (2021-2032)
- 5.7.3 South America Conjunctivitis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Conjunctivitis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Conjunctivitis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Conjunctivitis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Conjunctivitis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Conjunctivitis Sales by Type (2021-2032)
- 6.1.1 Global Conjunctivitis Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Conjunctivitis Sales Market Share by Type (2021-2032)
- 6.2 Global Conjunctivitis Revenue by Type (2021-2032)
- 6.2.1 Global Conjunctivitis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Conjunctivitis Revenue Market Share by Type (2021-2032)
- 6.3 Global Conjunctivitis Price by Type (2021-2032)
7 Segment by End User
- 7.1 Global Conjunctivitis Sales by End User (2021-2032)
- 7.1.1 Global Conjunctivitis Sales by End User (2021-2032) & (K Units)
- 7.1.2 Global Conjunctivitis Sales Market Share by End User (2021-2032)
- 7.2 Global Conjunctivitis Revenue by End User (2021-2032)
- 7.2.1 Global Conjunctivitis Sales by End User (2021-2032) & (US$ Million)
- 7.2.2 Global Conjunctivitis Revenue Market Share by End User (2021-2032)
- 7.3 Global Conjunctivitis Price by End User (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Conjunctivitis Value Chain Analysis
- 8.1.1 Conjunctivitis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Conjunctivitis Production Mode & Process
- 8.2 Conjunctivitis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Conjunctivitis Distributors
- 8.2.3 Conjunctivitis Customers
9 Global Conjunctivitis Analyzing Market Dynamics
- 9.1 Conjunctivitis Industry Trends
- 9.2 Conjunctivitis Industry Drivers
- 9.3 Conjunctivitis Industry Opportunities and Challenges
- 9.4 Conjunctivitis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst